Angle PLC Announces New Commercial Agreement with Large Pharma

ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies

GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has signed a supplier agreement to develop a Parsortix-based Androgen Receptor¹ (AR) detection assay for use in prostate cancer studies. The supplier agreement reported here is with AstraZeneca (LSE/STO/Nasdaq: AZN). This follows an earlier agreement to develop a methodology for CTC micronuclei detection using the Company's DNA Damage Response (DDR) assay, announced on 24 April 2024.

Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the Company supporting clinical studies.

AR is a nuclear protein involved in cell growth and proliferation, cell cycle progression, protein synthesis, and cell death. The analysis of Parsortix harvested CTCs using the Company's AR assay could enable longitudinal, minimally invasive assessment of AR status throughout clinical studies and during follow-up. There are more than 130 active, interventional oncology clinical studies in 30,000 participants, which include androgen receptor assessment, registered on clinicaltrials.gov.

ANGLE Chief Executive Officer, Andrew Newland, commented:

"This is further validation of ANGLE's Parsortix system which shows potential for long-term large-scale revenues in bringing innovative new cancer drugs to the market. We anticipate that success in this first phase of assay development may lead to much larger contracts for use of the assay in clinical trials."

ANGLE Chief Scientific Officer, Karen Miller commented:

"We are delighted our expertise is being put to use in the isolation, harvest, and profiling of CTCs for androgen receptor investigation with the potential for ANGLE's assays to be used in clinical trials. The new androgen receptor assay will also be an important addition to the menu of assays we can offer other customers."